Shortening Treatment for Multi-Drug Resistant Tuberculosis in Mice
Author Information
Author(s): Veziris Nicolas, Ibrahim Murad, Lounis Nacer, Andries Koen, Jarlier Vincent
Primary Institution: UPMC Université Paris 06
Hypothesis
The addition of TMC207 to the WHO recommended MDR TB regimen can reduce the treatment duration while maintaining efficacy.
Conclusion
The study suggests that the treatment duration for MDR TB could be reduced to 12 months, and potentially to 6 months with the inclusion of TMC207.
Supporting Evidence
- The addition of TMC207 reduced the treatment duration needed to achieve the same relapse rate.
- A completely oral regimen including TMC207 was effective in achieving similar relapse rates.
- The study indicates that the WHO MDR TB treatment duration could be reduced from 18-24 months to 12 months.
Takeaway
Researchers found that a new drug could help treat a serious lung disease faster, making it easier for people to get better.
Methodology
Swiss mice were infected with Mycobacterium tuberculosis and treated with various drug combinations to assess relapse rates.
Potential Biases
Potential bias due to the lack of human data to fully validate mouse model results.
Limitations
The study's small sample size may limit the statistical power and generalizability of the results.
Participant Demographics
Female Swiss mice, four weeks old.
Statistical Information
P-Value
p<0.005
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website